Skip to content

clinical study of different concentration of nalbuphine combined with hydromorphine on PCIA in patients undergoing cesarean section

clinical study of different concentration of nalbuphine combined with hydromorphine on PCIA in patients undergoing cesarean section

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015014
Enrollment
Unknown
Registered
2018-02-28
Start date
2018-02-28
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia of cesarean section

Interventions

0.5mg/ml nalbuphine + 0.05mg/ml hydromorphine:(0.5mg/ml nalbuphine + 0.05mg/ml hydromorphine + 0.9%NaCl)/120ml PCIA
0.7mg/ml nalbuphine + 0.05mg/ml hydromorphine:(0.7mg/ml nalbuphine + 0.05mg/ml hydromorphine + 0.9%NaCl)/120ml PCIA
0.9mg/ml nalbuphine + 0.05mg/ml hydromorphine:(0.9mg/ml nalbuphine + 0.05mg/ml hydromorphine + 0.9%NaCl)/120ml PCIA

Sponsors

Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 25-45 years oldselective cesarean section via longitudinal incision; 2. gestational weeks =37 weeks; 3. ASA I-II; 4. BMI is between 19-29 kg/m2; 5. Operation time is less than 2 hours; 6. voluntarily request postoperative analgesia.

Exclusion criteria

Exclusion criteria: 1. Serious medical complication including pre-eclampsia,gestational diabetes or pregnancy complicated with heart disease; 2. Opioid drugs,non-steroidal anti-inflammatory drugs are taking or are being taken 48 hours before the operation; 3. Who once had skin itching after the operation or an allergy to any of the study medications; 4. Changed the anesthetic methods during the operation; 5. Who Unable to cooperate with the doctor; 6. Impaired intestinal peristalsis and intestinal obstruction; 7. Participated in clinical trials of another drugs in the last 4 weeks.

Design outcomes

Primary

MeasureTime frame
VAS score of uterine contraction pain;VAS score of incisional pain;patients general satisfactory degree;The total consumption of 48 hours;

Secondary

MeasureTime frame
reality pressing numbers/effective pressing numbers D1/D2;sedation score;First self-maturate time;Apgar score;sedation score;Hospitalization time;

Countries

China

Contacts

Public ContactChunyun Huang

Women's Hospital School Of Medicine Zhejiang University

sunshingdays@126.com+86 15257192235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026